LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

Search

Charles River Laboratories International Inc

Fechado

SetorSaúde

178.46 1.8

Visão Geral

Variação de preço das ações

24h

Atual

Mín

177.84

Máximo

179.56

Indicadores-chave

By Trading Economics

Rendimento

-332M

-277M

Vendas

-11M

994M

EPS

2.43

Margem de lucro

-27.816

Funcionários

18,300

EBITDA

730K

198M

Recomendações

By TipRanks

Recomendações

Comprar

Previsão para 12 meses

+14.46% upside

Dividendos

By Dow Jones

Próximos Ganhos

6 de mai. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

107M

8B

Abertura anterior

176.66

Fecho anterior

178.46

Sentimento de Notícias

By Acuity

50%

50%

139 / 352 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Strong Bullish Evidence

Charles River Laboratories International Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

27 de fev. de 2026, 23:53 UTC

Ações em Alta

Stocks to Watch: Aardvark Therapeutics, Blue Moon Metals

27 de fev. de 2026, 22:23 UTC

Aquisições, Fusões, Aquisições de Empresas

Blue Moon Metals To Acquire Apex Germanium Mine From Teck Subsidiary

1 de mar. de 2026, 00:00 UTC

Notícias Principais

Trump's War on Iran Threatens to Drive Up Oil Prices and Inflation -- WSJ

28 de fev. de 2026, 21:36 UTC

Ganhos

Berkshire Hathaway Operating Earnings Fell 30% in Fourth Quarter. There Were No Stock Buybacks. -- Barrons.com

28 de fev. de 2026, 21:27 UTC

Notícias Principais

Iran Strikes Could Make Fed Rate Cuts Even Less Likely -- Barrons.com

28 de fev. de 2026, 15:20 UTC

Ganhos

Berkshire's Abel Pledges to Follow Buffett's 'Framework' in First Shareholder Letter -- 2nd Update

28 de fev. de 2026, 14:43 UTC

Ganhos

Berkshire Hathaway Operating Earnings Fell 30% in Fourth Quarter. There Were No Stock Buybacks. -- Barrons.com

28 de fev. de 2026, 14:40 UTC

Notícias Principais

What Defense Stocks Stand to Gain -- and Lose -- From the U.S. Attacks on Iran -- Barrons.com

28 de fev. de 2026, 14:38 UTC

Ganhos

Berkshire's Abel Pledges to Follow Buffett's 'Framework' in First Shareholder Letter -- Update

28 de fev. de 2026, 13:51 UTC

Notícias Principais

What Defense Stocks Stand to Gain--and Lose--From the US Attacks on Iran -- Barrons.com

28 de fev. de 2026, 13:47 UTC

Ganhos

Berkshire Hathaway Operating Earnings Fell 30% in Fourth Quarter. There Were No Stock Buybacks. -- Barrons.com

28 de fev. de 2026, 13:44 UTC

Ganhos

Berkshire Hathaway Earnings Slip on Decline in Insurance Results -- WSJ

28 de fev. de 2026, 13:14 UTC

Ganhos

Berkshire Hathaway Operating Earnings Fell 30% in Fourth Quarter. There Were No Stock Buybacks. -- Barrons.com

28 de fev. de 2026, 12:41 UTC

Notícias Principais

Iran's Rulers Face an All-Out Battle for Survival -- Barrons.com

28 de fev. de 2026, 10:30 UTC

Aquisições, Fusões, Aquisições de Empresas

All The Ways Netflix Actually Won Even Though It Lost Warner -- Heard on the Street -- WSJ

28 de fev. de 2026, 02:32 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

Calpers Buys Into Hot Chip And Quantum Stocks -- Barrons.com

28 de fev. de 2026, 02:00 UTC

Aquisições, Fusões, Aquisições de Empresas

Six Months, 9 Offers and $81 Billion. How Hollywood's Nasty Takeover Was Won. -- WSJ

28 de fev. de 2026, 02:00 UTC

Aquisições, Fusões, Aquisições de Empresas

Six Months, 9 Offers and $81 Billion. How -2-

28 de fev. de 2026, 00:01 UTC

Aquisições, Fusões, Aquisições de Empresas

Paramount Issuing $47 Billion of Equity at Big Premium to Stock Price for Warner Bros. Deal -- Barrons.com

27 de fev. de 2026, 23:46 UTC

Aquisições, Fusões, Aquisições de Empresas

Netflix Walks Away a Winner After Losing Warner Bros. to Paramount -- Barrons.com

27 de fev. de 2026, 23:33 UTC

Aquisições, Fusões, Aquisições de Empresas

Paramount Issuing $47 Billion of Equity at Nearly 20% Premium to Current Stock Price -- Barrons.com

27 de fev. de 2026, 21:50 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Tech, Media & Telecom Roundup: Market Talk

27 de fev. de 2026, 21:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

27 de fev. de 2026, 21:30 UTC

Ganhos

Solventum Beat Wall Street Earnings Estimates. The Stock Falls. -- Barrons.com

27 de fev. de 2026, 21:30 UTC

Conversa de Mercado
Aquisições, Fusões, Aquisições de Empresas

Warner Terminates Netflix Deal, Ending Monthslong Saga -- Market Talk

27 de fev. de 2026, 21:20 UTC

Aquisições, Fusões, Aquisições de Empresas

Blue Moon Metals to Buy Apex Germanium and Gallium Mine From Teck >BMM

27 de fev. de 2026, 21:17 UTC

Ganhos

These Stocks Are Today's Movers: Netflix, Paramount, Block, Sunrun, Dell, Rocket Lab, Nvidia, CoreWeave, and More -- Barrons.com

27 de fev. de 2026, 21:10 UTC

Aquisições, Fusões, Aquisições de Empresas

Blue Moon Metals Evaluating Options for a New Processing Line at Springer Complex to Process the Apex Material

27 de fev. de 2026, 21:09 UTC

Aquisições, Fusões, Aquisições de Empresas

Blue Moon Metals to Acquire the Apex Germanium and Gallium Mine From Teck

27 de fev. de 2026, 21:00 UTC

Ganhos

Nike: 3Q Results to Be Released March 31 to Accommodate for Several Holidays >NKE

Comparação entre Pares

Variação de preço

Charles River Laboratories International Inc Previsão

Preço-alvo

By TipRanks

14.46% parte superior

Previsão para 12 meses

Média 204.3 USD  14.46%

Máximo 265 USD

Mínimo 175 USD

Com base em 12 analistas de Wall Street que oferecem metas de preço de 12 meses para Charles River Laboratories International Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Comprar

12 ratings

8

Comprar

4

Manter

0

Vender

Pontuação Técnica

By Trading Central

117.16 / 144.77Suporte e Resistência

Curto Prazo

Strong Bullish Evidence

Médio Prazo

Weak Bullish Evidence

Longo Prazo

Bearish Evidence

Sentimento

By Acuity

139 / 352 Ranking em Saúde

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Charles River Laboratories International Inc

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
help-icon Live chat